Business Context and Reporting Period
OKYO Pharma Ltd, a foreign private issuer, filed Form 6-K on February 12, 2026. The filing announces the Company's intention to conduct an underwritten public offering of its ordinary shares. Piper Sandler & Co. is serving as the sole book-running manager for the proposed transaction.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report serves solely as a notice of a potential capital raise and does not contain financial statements or operational metrics.
Material Changes
No material changes to financial performance or operations are reported in this filing. The primary change is the initiation of a planned public offering, which is subject to market conditions.
Guidance, Outlook, and Risks
- Offering Structure: The Company intends to sell all ordinary shares in the offering. A 30-day option to purchase up to an additional 15% of the shares sold may be granted to the underwriter.
- Uncertainty: The Offering is subject to market conditions. There is no assurance regarding whether or when the Offering will be completed, nor regarding its final size or terms.
- Legal Status: The accompanying news announcement (Exhibit 99.1) is furnished but not deemed "filed" under Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Confirm the final terms, size, and pricing of the public offering once the prospectus is filed.
- Verify whether the 15% over-allotment option is exercised by the underwriter.
- Review the Company's most recent Form 20-F for actual financial performance data, as this 6-K contains none.
- Monitor market conditions that could delay or cancel the proposed Offering.